<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[International Journal of Ophthalmology Press -->专家述评]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical research progress of Boston type I keratoprosthesis]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/201501001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Boston Type I keratoprosthesis is currently widely used. In this article, the indication, number of cases, best-corrected visual acuity(BCVA), retention, and complications in all the international published case reports will be sum up; then the main post-operative complications and their respective treatments one by one, which include retrospective membrane, glaucoma, infection will be introduced.]]></description>
<pubDate>2014/12/30 0:00:00</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Jia-Qi Chen and Jia-Jie Zhai]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Jia-Qi Chen and Jia-Jie Zhai</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/201501001]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[New coronavirus pneumonia COVID-19 and ocular surface transmission]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202003001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Since the end of 2019, the novel coronavirus pneumonia(COVID-19)has rapidly spread in Wuhan City, Hubei Province of China. This has aroused great concern of the Chinese government and the international community. There have been unconfirmed threads of COVID-19 patients with conjunctivitis as the first symptom. Therefore, the issue that whether and how the novel coronavirus strain SARS-CoV-2 infection is transmitted through the ocular surface has become a new concern. In the absence of clinical and experimental evidence of COVID-19 in ocular infection, we have conducted a retrospective literature analysis of viral pathogens that simultaneously trigger ocular lesions during the onset of epidemic diseases. The purpose of this paper is to provide some reference and suggestions for appropriately understanding of ocular protection in the prevention and control of the COVID-19.]]></description>
<pubDate>2020/3/13 19:43:56</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Ming-Zhi Zhang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Ming-Zhi Zhang</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202003001]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[European Society of Retina Specialists guidelines for management of diabetic macular edema]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202001001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Diabetic retinal disease(DRD)is a disease with a sharp increase in the proportion of retinal disease(RD). Diabetic macular edema is the leading cause of vision loss. The treatment of diabetic macular edema has always been a hot topic in medicine. The diagnosis and treatment of diabetic macular edema is the latest treatment guideline for diabetic macular edema published by the European Association of Retinal Experts. It is considered to be the most representative guide at present. Detailed interpretation in this article will help the majority of ophthalmologists have a new understanding of the diagnosis and treatment of diabetic macular edema.]]></description>
<pubDate>2019/12/20 14:53:53</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Yi Shao, Shan-Shan Wang and Qing Yuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yi Shao, Shan-Shan Wang and Qing Yuan</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202001001]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Perifoveal exudative vascular anomalous complex]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202209001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Parafoveal exudative vascular anomalous complex(PEVAC)refers to a large, isolated aneurysmal lesion in the superficial or deep capillary plexus of the parafoveal retina demonstrated by optical coherence tomography(OCT)imaging and has been identified as a new entity. Patients are almost middle-aged and elder people, not accompanied by retinal vascular diseases, but can develop with myopic or age-related macular degeneration(ARMD). It has been defined as PEVAC-resembling lesions when associated with retinal vascular diseases, such as diabetic retinopathy(DR)or retinal vein occlusion. It is non-exudative in the early stage, but later intraretinal exudation may induce metamorphopsia or visual decline. In some cases, the lesion was unchanged or spontaneously resolved during long-term follow-up.Differentiation from type 3 retinal neovascularization(retinal angiomatous proliferation, RAP)and Type I MacTel may be required. The anti-vascular endothelial growth factor(VEGF)therapy is ineffective and micropulse laser treatment could achieve improvement in a few cases. It is speculated that the lesion is associated with degeneration of retinal microvascular pericytes.]]></description>
<pubDate>2022/9/2 14:23:08</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Yan-Nian Hui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yan-Nian Hui</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202209001]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Guidelines for the application of the fundus autofluorescence in age-related macular degeneration(2023)]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202308001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Fundus autofluorescence(FAF)imaging is based on the fluorescence excited by the endogenous fluorophores in the retinal pigment epithelium and choroid, mainly referring to lipofuscin(LF)and melanin. The non-invasive examination method can imply the function of retinal pigment epithelium by observing the spatial distribution of LF or melanin. This technique has unique advantages in the diagnosis and differentiation of age-related macular degeneration(ARMD). This guideline is to standardize and interpret the application of FAF in different stages and classifications of ARMD.]]></description>
<pubDate>2023/7/25 11:03:24</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Yi Shao, Wei Chi, Yan-Tao Wei, Expert Workgroup of Guidelines for the Application of the Fundus Autofluorescence in Age-related Macular Degeneration (2023), Ophthalmic Imaging and Intelligent Medicine Branch of China Medical Education Association, Ophthalmology Branch of World Association of Translational Medicine and Chinese Ophthalmic Imaging Study Groups]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yi Shao, Wei Chi, Yan-Tao Wei, Expert Workgroup of Guidelines for the Application of the Fundus Autofluorescence in Age-related Macular Degeneration (2023), Ophthalmic Imaging and Intelligent Medicine Branch of China Medical Education Association, Ophthalmology Branch of World Association of Translational Medicine and Chinese Ophthalmic Imaging Study Groups</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202308001]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[How internal limiting membrane peeling revolutionized macular surgery in the last three decades]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202307001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[As a major innovation in macular surgery over the past 30 years,internal limiting membrane peeling has now become standard operation after all-round improvements. However, how to achieve optimal response and avoid poor prognosis by peeling the internal limiting membrane, which is the basement membrane of the Müller cells representing the structural interface between retina and vitreous, still needs to be explored. Prof. Peter Wiedemann, the co-editor-in-chief of our journal, in view of his long-term outstanding contributions to retinal surgery and the important progress his team has made in foveal regeneration, wrote this review with a special invitation. He gladly completed this article in 2wk, which is comprehensive, outlined, insightful, concise and shining with wisdom. It summarizes the history, rationale, techniques, indications, size and adverse outcomes of internal limiting membrane peeling and the surgery for refractory macular hole. It not only affirms current cognition, but raises existing problems, which are worthy reading and reflecting, so it was translated for readers' convenience.]]></description>
<pubDate>2023/6/21 14:36:08</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Peter Wiedemann and Yan-Nian Hui(Translator)]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Peter Wiedemann and Yan-Nian Hui(Translator)</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202307001]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Statistical predictive model nomogram applied in ophthalmology]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202307002]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The alignment diagram, also known as nomogram, is a statistical prediction model used to predict the risk of events(such as diagnosis or prediction of disease development and consequences)by obtaining the influence power of each related factor on outcome variables through multivariate analysis. Nomogram turns the complex regression equation to a visualized diagram that is intuitive and easy to understand. It is convenient to be used for evaluating the patient's condition and communicating with doctors and patients. With rapid advances of medical science and technology and increasing demands of personalized medicine, nomograms has attracted more and more attention and applied extensively in clinical medicine. This short article introduces the basic concepts of nomogram and examples of its application in ophthalmology.]]></description>
<pubDate>2023/6/21 14:36:08</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Yan-Nian Hui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yan-Nian Hui</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202307002]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Guidelines on Clinical Research Evaluation of Artificial Intelligence in Ophthalmology(2023)]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202307003]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the upsurge of artificial intelligence(AI)technology in the medical field, its application in ophthalmology has become a cutting-edge research field. Notably, machine learning techniques have shown remarkable achievements in diagnosing, intervening, and predicting ophthalmic diseases. To meet the requirements of clinical research and fit the actual progress of clinical diagnosis and treatment of ophthalmic AI, the Ophthalmic Imaging and Intelligent Medicine Branch and the Intelligent Medicine Special Committee of Chinese Medicine Education Association organized experts to integrate recent evaluation reports of clinical AI research at home and abroad and formed a guideline on clinical research evaluation of AI in ophthalmology after several rounds of discussion and modification. The main content includes the background and method of developing this guideline, introduction to international guidelines on the clinical research evaluation of AI, and the evaluation methods of ophthalmic AI models. This guideline introduces general evaluation methods of clinical ophthalmic AI research, evaluation methods of clinical AI models, and common indices and formulae for clinical AI model evaluation in detail, and amply elaborates the evaluation method of clinical ophthalmic AI trials. This guideline aims to provide guidance and norms for clinical researchers of ophthalmic AI, promote the development of regularization and standardization, and further improve the overall level of clinical ophthalmic AI research evaluations.]]></description>
<pubDate>2023/6/21 14:36:08</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Wei-Hua Yang, Yi Shao, Yan-Wu Xu, Expert Workgroup of Guidelines on Clinical Research Evaluation of Artificial Intelligence in Ophthalmology (2023), Ophthalmic Imaging and Intelligent Medicine Branch of Chinese Medicine Education Association and Intelligent Medicine Special Committee of Chinese Medicine Education Association]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Wei-Hua Yang, Yi Shao, Yan-Wu Xu, Expert Workgroup of Guidelines on Clinical Research Evaluation of Artificial Intelligence in Ophthalmology (2023), Ophthalmic Imaging and Intelligent Medicine Branch of Chinese Medicine Education Association and Intelligent Medicine Special Committee of Chinese Medicine Education Association</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202307003]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Neurovascular unit and diabetic retinopathy]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202303001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The concept of neurovascular unit(NVU), formalized in 2001 at a stroke conference, emphasizes the intimate relationship between the brain and its vessels, i.e., symbiotic relationship between brain cells and cerebral blood vessels in the developmental, structural and functional interdependence. The retina is a piece of brain. Several researchers have introduced the concept of NVU to the retina since 2007. The NVU in the retina includes neurons, glial cells, microvascular endothelial cells and pericytes. Dysfunctional NVU plays a critical role in diabetic retinopathy(DR). The current limited treatments for DR focus on the late-stage complications, i.e., diabetic macular edema and proliferative DR. While the further study on retinal NVU will develop efficacious therapeutic options for the early and all stages of DR.]]></description>
<pubDate>2023/3/2 16:43:33</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Yan-Nian Hui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yan-Nian Hui</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202303001]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Peripapillary pachychoroid syndrome: A novel entity of pachychoroid disease spectrum]]></title>
<link><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202301001]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Peripapillary pachychoroid syndrome(PPS)is a novel entity of pachychoroid disease spectrum(PDS)reported online in 2017. PPS eyes displayed thicker nasal versus temporal macular choroids, unlike PDS eyes with thicker temporal macular choroids. Peripapillary intraretinal and/or subretinal fluid was often overlying dilated Haller layer vessels(pachyvessels). Most PPS eyes exhibited other PDS findings including retinal pigment epithelial changes, serous pigment epithelial detachment and outer retinal atrophy. Their optic disc is usually crowded, and some eyes have disc edema and mild late fluorescence leakage. Most of the patients are elderly, and short axial length and hyperopia are common. While some patients experienced visual decline, the overall visual outcome was relatively favourable. Although anti-VEGF or photodynamic therapy were applied, the optimal management remains to be determined. Recognition of PPS is important to distinguish it from disorders with overlapping features such as posterior uveitis and neuro-ophthalmologic conditions. It has been suggested that PDS is consequences of chronic vortex vein stasis. And the hypothesis of choroidal venous overload provides with a unifying concept for pathophysiology of the diseases.]]></description>
<pubDate>2023/1/4 15:06:18</pubDate>
<category><![CDATA[专家述评]]></category>
<author><![CDATA[Yan-Nian Hui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>Yan-Nian Hui</atom:name>
</atom:author>
<guid><![CDATA[http://ies.ijo.cn/gjyke/article/abstract/202301001]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>